Shenzhen Hepalink Pharmaceutical Group Co (SZSE:002399) Accounts Payable & Accrued Expense : ¥1,113 Mil (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Shenzhen Hepalink Pharmaceutical Group Co Accounts Payable & Accrued Expense?

Shenzhen Hepalink Pharmaceutical Group Co's quarterly accounts payable & accrued expense increased from Sep. 2023 (¥892 Mil) to Dec. 2023 (¥957 Mil) and increased from Dec. 2023 (¥957 Mil) to Mar. 2024 (¥1,113 Mil).

Shenzhen Hepalink Pharmaceutical Group Co's annual accounts payable & accrued expense declined from Dec. 2021 (¥1,104 Mil) to Dec. 2022 (¥1,085 Mil) and declined from Dec. 2022 (¥1,085 Mil) to Dec. 2023 (¥957 Mil).

Shenzhen Hepalink Pharmaceutical Group Co Accounts Payable & Accrued Expense Historical Data

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Hepalink Pharmaceutical Group Co Accounts Payable & Accrued Expense Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

813.33

836.65

1,103.99

1,085.44

957.25

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															1,016.96	1,227.51	891.66	957.25	1,113.20

Shenzhen Hepalink Pharmaceutical Group Co Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Shenzhen Hepalink Pharmaceutical Group Co (SZSE:002399) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Hepalink Pharmaceutical Group Co Ltd (SZSE:002399) » Definitions » Accounts Payable & Accrued Expense

Traded in Other Exchanges

09989:Hong Kong

Address

No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057

Website

https://www.hepalink.com

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business and Others. Geographical presence of company is in Hong Kong, United States of America, Europe, Mainland China and Other countries. Majority of the company's revenue comes from USA and Europe.

Executives

Zhang Ping	Director
Li Li	Director
Kong Yun	Executives
Li Tan	Directors, executives

Shenzhen Hepalink Pharmaceutical Group Co (SZSE:002399) Headlines

No Headlines